Malignant pleural mesothelioma: some progress, but still a long way from cure.

about

Malignant pleural mesothelioma: some progress, but still a long way from cure.

Item

http://www.wikidata.org/entity/Q55064382

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Malignant pleural mesothelioma: some progress, but still a long way from cure.

@en

Malignant pleural mesothelioma: some progress, but still a long way from cure.

@nl

type

Item

label

Malignant pleural mesothelioma: some progress, but still a long way from cure.

@en

Malignant pleural mesothelioma: some progress, but still a long way from cure.

@nl

prefLabel

Malignant pleural mesothelioma: some progress, but still a long way from cure.

@en

Malignant pleural mesothelioma: some progress, but still a long way from cure.

@nl

P1476

Malignant pleural mesothelioma: some progress, but still a long way from cure.

@en

P2093

Loic Lang-Lazdunski

http://www.w3.org/2001/XMLSchema#string

P2860

Mesothelioma treatment: Are we on target? A review

Mesothelin Immunotherapy for Cancer: Ready for Prime Time?

Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.

Novel systemic therapy against malignant pleural mesothelioma.

Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study.

Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma.

Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival.

A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.

LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.

P304

1172-1177

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.21037/JTD.2018.01.152

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29708163

http://www.w3.org/2001/XMLSchema#string

P932

5906350

http://www.w3.org/2001/XMLSchema#string